Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Camp4 Therapeutics (CAMP) Liabilities and Shareholders Equity: 2023-2025

Historic Liabilities and Shareholders Equity for Camp4 Therapeutics (CAMP) over the last 1 years, with Sep 2025 value amounting to $86.4 million.

  • Camp4 Therapeutics' Liabilities and Shareholders Equity rose 304.40% to $86.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $278.8 million, marking a year-over-year change of. This contributed to the annual value of $78.3 million for FY2024, which is 42.52% up from last year.
  • Camp4 Therapeutics' Liabilities and Shareholders Equity amounted to $86.4 million in Q3 2025, which was up 68.49% from $51.3 million recorded in Q2 2025.
  • In the past 5 years, Camp4 Therapeutics' Liabilities and Shareholders Equity registered a high of $86.4 million during Q3 2025, and its lowest value of $21.4 million during Q3 2024.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $58.9 million (2023), whereas its average is $59.2 million.
  • Data for Camp4 Therapeutics' Liabilities and Shareholders Equity shows a peak YoY soared of 304.40% (in 2025) over the last 5 years.
  • Over the past 3 years, Camp4 Therapeutics' Liabilities and Shareholders Equity (Quarterly) stood at $54.9 million in 2023, then surged by 42.52% to $78.3 million in 2024, then soared by 304.40% to $86.4 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $86.4 million for Q3 2025, versus $51.3 million for Q2 2025 and $62.8 million for Q1 2025.